Shigeki Yagyu – VJRegenMed

PiggyBac Transposon-generated CAR T-cells in solid tumors

Simon Ng — Thu, 21 Apr 2022 16:45:47 +0000

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, discusses the future of PiggyBac transposon-mediated chimeric antigen receptor (CAR) T-cell therapies. A clinical trial is imminently underway to assess a CAR T-cell therapy based on PiggyBac transposon technology in HER2+ bone sarcoma and gynecological cancers. Preclinical studies assessing the treatment has yielded promising results in sarcoma and brain tumors in terms of efficacy and long-term functionality. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

CAR T-cell therapy for neuroblastoma

Simon Ng — Thu, 21 Apr 2022 16:45:46 +0000

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, gives an overview of promising chimeric antigen receptor (CAR) T-cell therapies for neuroblastoma. Despite current immunotherapies such as dinutuximab and naxitamab being available, prognoses remain poor in patients. PiggyBac transposon-mediated chimeric antigen receptor (CAR) T-cell therapies represent an alternative option for patients and clinical trials are underway to assess safety and efficacy. The PiggyBac transposon will hopefully solve issues relating to cell exhaustion and tumor control and the technology may potentially be utilized in natural killer (NK) cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Enhancing the long-term functionality of CAR-T cells in solid tumors

Simon Ng — Mon, 11 Apr 2022 09:52:51 +0000

The efficacy of chimeric antigen receptor (CAR) T-cell therapy in solid tumors have been substandard as a result of CAR T-cell differentiation and exhaustion. Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, comments on the need to improve CAR T-cell potency in solid tumors by optimizing long-term functionality. Despite lentiviral vectors predominantly being used in the engineering of CAR T-cell therapies, they may affect T-cell activity during cell expansion. Dr Yagyu discusses strategies to boost CAR T-cell efficacy including lowering PD-1 expression and reducing T-cell exhaustion. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

The benefits of PiggyBac transposon-mediated CAR-T cell technology

Simon Ng — Mon, 11 Apr 2022 09:52:49 +0000

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, describes the advantages of PiggyBac transposon-based chimeric antigen receptor (CAR) T-cells. As utilizing viral vectors in T-cell expansion can compromise the efficacy of the CAR T-cells and cause differentiation and T-cell exhaustion, PiggyBac transposons represent a viable alternative to manufacture CAR T-cells. Resting T-cells as a base can prevent exhaustion and using antigen-presenting cells (APCs) instead of CD3 can successfully induce the expansion of T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.